XML 51 R45.htm IDEA: XBRL DOCUMENT v3.26.1
Segment Reporting - Summary of Financial Information of Reportable Segment (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting Information [Line Items]            
Total R&D program expense $ 44,437   $ 61,030   $ 86,560 $ 102,489
Equity-based compensation         16,063 19,261
Loss from operations (57,254)   (75,798)   (110,951) (130,794)
Interest income 3,648   5,924   7,746 12,504
Other expense, net (98)   (181)   (160) (266)
Net loss (53,704) $ (49,661) (70,055) $ (48,501) (103,365) (118,556)
Operating Segments [Member]            
Segment Reporting Information [Line Items]            
Total R&D program expense 31,062   27,008   59,387 54,669
Equity-based compensation 8,447   9,887   16,063 19,261
R&D personnel and operations 9,070   9,741   18,909 19,572
General and administrative personnel 3,589   3,335   7,384 6,824
License agreement obligations 0   20,115   0 20,153
Other segment expenses [1] 5,086   5,712   9,208 10,315
Loss from operations (57,254)   (75,798)   (110,951) (130,794)
Interest income 3,648   5,924   7,746 12,504
Other expense, net (98)   (181)   (160) (266)
Net loss (53,704)   (70,055)   (103,365) (118,556)
Operating Segments [Member] | CLN-049 [Member]            
Segment Reporting Information [Line Items]            
Total R&D program expense 6,009   4,898   11,068 8,793
Operating Segments [Member] | CLN-617 [Member]            
Segment Reporting Information [Line Items]            
Total R&D program expense 79   1,403   764 3,196
Operating Segments [Member] | CLN-619 [Member]            
Segment Reporting Information [Line Items]            
Total R&D program expense 1,102   7,317   3,573 13,435
Operating Segments [Member] | CLN-978 [Member]            
Segment Reporting Information [Line Items]            
Total R&D program expense 10,532   5,393   20,197 10,066
Operating Segments [Member] | Early-stage programs [Member            
Segment Reporting Information [Line Items]            
Total R&D program expense 1,116   1,986   1,825 3,008
Operating Segments [Member] | Velinotamig [Member]            
Segment Reporting Information [Line Items]            
Total R&D program expense 3,951   10   6,754 10
Operating Segments [Member] | Zipalertinib [Member]            
Segment Reporting Information [Line Items]            
Total R&D program expense $ 8,273   $ 6,001   $ 15,206 $ 16,161
[1] Other segment expenses for the three and six months ended June 30, 2026 and 2025 include legal fees relating to patent and corporate matters; professional fees for accounting, auditing, tax, and administrative consulting services; insurance costs; marketing expenses; depreciation; and other operating costs.